Acoustic Neuroma

🧠 Standard of Care & Symptoms

Acoustic Neuroma, medically known as Vestibular Schwannoma, is a benign, slow-growing myelin-forming tumor originating from the Schwann cells of the vestibular division of the vestibulocochlear nerve (cranial nerve VIII).

• Presentation: Slow onset of unilateral hearing and vestibular deficits.
  • Unilateral Auditory Deficits: Progressive sensorineural hearing loss (often noticed during telephone calls) and high-pitched unilateral tinnitus (ringing in the ear) are the initial symptoms in > 90% of cases.
  • Vestibular Dysfunction: Mild instability, unsteadiness, or disequilibrium. Acute rotational vertigo is rare due to slow compensation by the cerebellum.
  • Cranial Nerve Compression: Larger tumors (> 2 cm) can compress the facial nerve (cranial nerve VII), causing facial weakness or spasms, or the trigeminal nerve (cranial nerve V), causing facial numbness or tingling.
• Genetic Predisposition: Most acoustic neuromas are unilateral and sporadic. Bilateral acoustic neuromas are the pathognomonic hallmark of **Neurofibromatosis Type 2 (NF2)**, a genetic syndrome caused by mutation of the NF2 tumor suppressor gene coding for the protein **merlin**.

🧬 Diagnostics & Auditory Mapping

Early diagnosis relies on standardized audiometric screens followed by high-resolution neuroimaging.

• Audiometric Evaluation: Demonstrates unilateral or asymmetric sensorineural hearing loss, often characterized by disproportionately poor word recognition (speech discrimination) relative to pure-tone thresholds.
• Magnetic Resonance Imaging (MRI): Gold standard. **Gadolinium-enhanced T1-weighted MRI** of the brain and internal auditory canals reveals a well-circumscribed, enhancing mass in the internal auditory canal (IAC) extending into the cerebellopontine angle (CPA), displaying a classic "ice cream cone" configuration.
• Auditory Brainstem Response (ABR): Used as a screening tool when MRI is contraindicated. Shows wave V latency delays on the affected side.

Antoni A & B Cellular Architecture & Merlin Deficits

The development and microenvironment of vestibular schwannomas exhibit specific cellular characteristics:

• Antoni A (Cellular/Verocay Bodies): Histology reveals regions of dense cellularity composed of elongated, spindle-shaped Schwann cells. The nuclei of these cells form parallel, palisading columns. The intervening, acellular eosinophilic fibers form structured complexes known as **Verocay bodies**.
• Antoni B (Hypocellular/Myxoid): Consists of a loose, myxoid tissue pattern with scattered cells, inflammatory cells, and microcysts. Antoni B areas feature prominent, thick-walled, hyalinized blood vessels that are prone to thrombosis.
• Merlin and Contact Inhibition Loss: Sporadic and NF2-associated tumors are driven by inactivation of the **NF2 tumor suppressor gene** on chromosome 22q12. This gene encodes **merlin** (schwannomin), a membrane-organizing scaffold protein. Merlin loss disrupts contact inhibition pathways and deregulates receptor tyrosine kinase signaling (e.g., ErbB2/ErbB3), driving uncontrolled Schwann cell proliferation.

💊 Microsurgery & Stereotactic Radiosurgery

Management is highly individualized, based on tumor size, growth rate, age, health status, and baseline hearing levels.

1. Active Surveillance ("Watch and Wait")

• Indicated for small, asymptomatic tumors (< 1.5 cm) or older patients. Involves serial brain MRIs and audiograms every 6 to 12 months. Up to 50% of small tumors show no growth over several years.

2. Stereotactic Radiosurgery (SRS)

• Gamma Knife or CyberKnife: Delivers a highly focused, single or fractionated dose of radiation to arrest tumor growth by causing vascular thrombosis and tumor cell necrosis. SRS has a > 90% tumor control rate for small-to-medium tumors, preserving pre-treatment hearing in many cases, though it does not remove the physical mass.

3. Microsurgical Resection

• Indicated for large, growing tumors, brainstem compression, or failed radiation. Approaches include:
  • Translabyrinthine Approach: Sacrifices hearing; provides excellent facial nerve exposure and minimizes cerebellar retraction.
  • Retrosigmoid (Suboccipital) Approach: Offers potential for hearing preservation in small-to-medium tumors.
  • Middle Cranial Fossa Approach: Used for small intracanalicular tumors where hearing preservation is a priority.

🔬 Active Clinical Trials

Clinical trials are currently evaluating novel systemic biological therapies for NF2 (e.g., bevacizumab), optimized fractionation protocols for stereotactic radiosurgery, and surgical navigation systems.

🗺️ Next Steps After Diagnosis

If you have recently been diagnosed with an Acoustic Neuroma, follow these clinical pathways:

1. Obtain a Baseline Audiogram: Perform a comprehensive hearing evaluation to quantify pure-tone thresholds and word recognition percentages.
2. Consult a Multidisciplinary Skull Base Team: Seek opinions from both a neurotologist (ENT specialist) and a neurosurgeon experienced in skull base tumors.
3. Define Your Management Strategy: Work with your specialists to compare active surveillance, Gamma Knife radiosurgery, and microsurgical removal based on your tumor's size.
4. Watch for Pressure Symptoms: Seek emergency care if you experience severe headaches, nausea, vomiting, double vision, or difficulty walking (ataxia), which indicate brainstem compression or hydrocephalus.

❓ Patient FAQ

Q: Is an acoustic neuroma a type of brain cancer? Will it spread to other organs?
A: No. Acoustic neuroma is a completely benign (non-cancerous) tumor. It does not invade brain tissue, and it cannot metastasize or spread to other parts of your body. However, because it is located inside the skull, it is considered clinically serious. As it grows, it can compress vital cranial nerves and the brainstem, which can be life-threatening if left untreated.

Q: Will I lose my hearing permanently after surgery or radiation?
A: It depends on your tumor size and baseline hearing. If you undergo translabyrinthine surgery, your hearing on the operated side will be completely lost. Other surgical approaches (retrosigmoid or middle fossa) offer a chance of preserving hearing, but it is not guaranteed. Stereotactic radiosurgery preserves pre-treatment hearing levels in about 50-70% of patients long-term, though gradual hearing decline can still occur over time.